Cargando…
Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo
Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CD19 CAR) T-cell therapy in lymphoma, but t...
Autores principales: | Ye, Xiupeng, Liu, Meijing, Lv, Cuicui, Li, Yeqiong, Chen, Lan, Zhang, Jin, Mu, Juan, Deng, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580088/ https://www.ncbi.nlm.nih.gov/pubmed/36254554 http://dx.doi.org/10.1177/15330338221133224 |
Ejemplares similares
-
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
por: Liu, Meijing, et al.
Publicado: (2020) -
Anti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model
por: Xiao, Qian, et al.
Publicado: (2023) -
Effect of Meloxicam on the Proliferation and Apoptosis of the Raji Cell Line: an In Vitro Study
por: Asmarani, Yolanda Kartika, et al.
Publicado: (2022) -
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021) -
CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
por: Jiang, Shuang, et al.
Publicado: (2016)